ATE372129T1 - Impfstoff von umhüllten viren und verfahren zu seiner herstellung - Google Patents

Impfstoff von umhüllten viren und verfahren zu seiner herstellung

Info

Publication number
ATE372129T1
ATE372129T1 AT02796598T AT02796598T ATE372129T1 AT E372129 T1 ATE372129 T1 AT E372129T1 AT 02796598 T AT02796598 T AT 02796598T AT 02796598 T AT02796598 T AT 02796598T AT E372129 T1 ATE372129 T1 AT E372129T1
Authority
AT
Austria
Prior art keywords
production
virus vaccine
purified
enclosed
rrv
Prior art date
Application number
AT02796598T
Other languages
English (en)
Inventor
Otfried Kistner
Manfred Reiter
Axel Bruehmann
Noel Barrett
Wolfgang Mundt
Friedrich Dorner
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of ATE372129T1 publication Critical patent/ATE372129T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C07K16/116—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
AT02796598T 2001-12-10 2002-12-10 Impfstoff von umhüllten viren und verfahren zu seiner herstellung ATE372129T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/006,671 US7195905B2 (en) 2001-12-10 2001-12-10 Enveloped virus vaccine and method for production

Publications (1)

Publication Number Publication Date
ATE372129T1 true ATE372129T1 (de) 2007-09-15

Family

ID=21722030

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02796598T ATE372129T1 (de) 2001-12-10 2002-12-10 Impfstoff von umhüllten viren und verfahren zu seiner herstellung

Country Status (7)

Country Link
US (4) US7195905B2 (de)
EP (1) EP1453535B1 (de)
AT (1) ATE372129T1 (de)
AU (1) AU2002361382B2 (de)
DE (1) DE60222296T2 (de)
NZ (1) NZ533869A (de)
WO (1) WO2003049765A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101169468B1 (ko) 2002-04-26 2012-08-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드시스템
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
KR101357443B1 (ko) 2003-02-25 2014-02-06 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
GB0524782D0 (en) * 2005-12-05 2006-01-11 Chiron Srl Analysis of samples
ES2523587T3 (es) * 2007-06-18 2014-11-27 Medimmune, Llc Virus influenza B que tienen alteraciones en el polipéptido hemaglutinina
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US11268071B2 (en) * 2017-03-30 2022-03-08 Merck Sharp And Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
TWI650398B (zh) 2017-12-08 2019-02-11 Chi Mei Corporation 發光材料與應用之顯示裝置
US20240241020A1 (en) * 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
WO2026013633A1 (en) * 2024-07-12 2026-01-15 Csl Behring Llc Methods of purifying an enveloped virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
DK1213030T3 (da) 1994-11-10 2009-07-20 Baxter Healthcare Sa Fremgangsmåde til fremstilling af biologiske produkter i protein-fri kultur
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
DK1285080T3 (da) 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler

Also Published As

Publication number Publication date
AU2002361382A1 (en) 2003-06-23
US20160199478A1 (en) 2016-07-14
WO2003049765A2 (en) 2003-06-19
US20030108859A1 (en) 2003-06-12
US20130078261A1 (en) 2013-03-28
AU2002361382B2 (en) 2008-06-12
US20070141617A1 (en) 2007-06-21
WO2003049765A3 (en) 2003-10-02
EP1453535B1 (de) 2007-09-05
DE60222296T2 (de) 2008-06-05
US20170035874A9 (en) 2017-02-09
US7195905B2 (en) 2007-03-27
DE60222296D1 (de) 2007-10-18
EP1453535A2 (de) 2004-09-08
NZ533869A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
ATE542829T1 (de) Impfstoff
CY1108789T1 (el) Καθαρισμος αντιγονων hbv για χρηση σε εμβολια
NO20023829L (no) Proteosom influensavaksine
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DE60226911D1 (de) Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
EA200700496A1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
EP1301208A4 (de) Impfstoff
ATE507286T1 (de) Immunisierung von fischen gegen virusinfektion
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
NL300336I1 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
WO2004032599A3 (en) Novel immunogenic proteins of leptospira
EP1667634A4 (de) Anthrax-vakzine
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
WO2002096940A3 (en) Attenuated very virulent infectious bursal disease virus
ATE348888T1 (de) Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen
ECSP034474A (es) Nuevo tratamiento

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1453535

Country of ref document: EP